Pfizer says Sutent breast cancer trials fail

Category Health | Saturday, March 13th, 2010

LOS ANGELES, March 11 (Reuters) – Pfizer Inc (PFE.N) said on Thursday that two late-stage breast cancer trials involving its cancer drug Sutent failed to meet their goals and it has stopped a pivotal lung cancer trial of experimental drug figitumumab.

Pfizer said outside monitors concluded that the Phase 3 trial of figitumumab in patients with previously treated advanced non-small cell lung cancer was unlikely to show that the drug was effective.

The world’s largest drugmaker is seeking new medicines as patents begin to expire on many of its top-selling products.

Related Amazon.com

Keyword: breast Cancer, Cancer Drug, Cancer Trials, Cell Lung Cancer, Experimental Drug, Lung Cancer, March 11, Monitors, New Medicines, Non Small Cell Lung Cancer, Patents, Pfe, Pfizer, Pfizer Inc, Phase 3, Reuters, Small Cell Lung Cancer, Stage Breast Cancer